OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Bahary on Treatment Strategies for Right- Versus Left-Sided Tumors in CRC

October 27th 2020

Nathan Bahary, MD, PhD, discusses treatment strategies for right- versus left-sided tumors in colorectal cancer.

Dr. Jacobson on the Significance of CD19-Targeted CAR T-Cell Therapy in B-Cell Malignancies

October 27th 2020

Caron Jacobson, MD, discusses the significance of CD19-targeted CAR T-cell therapy in B-cell malignancies.

Dr. Ahn on the Significance of the KEYNOTE-177 Trial in mCRC

October 27th 2020

Daniel H. Ahn, DO, discusses the significance of the phase 3 KEYNOTE-177 trial in patients with microsatellite instability–high metastatic colorectal cancer.

Dr. Galligan on Unmet Needs in High-Risk Multiple Myeloma

October 27th 2020

Derek C. Galligan, MD, discusses unmet needs in high-risk multiple myeloma.

Dr. Isaacs on the Evolving Treatment Landscape in HER2+ Breast Cancer

October 27th 2020

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Dr. Boutros on Processes That Predict Lethality in Prostate Cancer

October 26th 2020

Paul C. Boutros, PhD, MBA, discusses processes that predict disease lethality in men with prostate cancer.

Dr. Danilov on the Role of Chemoimmunotherapy in CLL

October 26th 2020

Alexey V. Danilov, MD, PhD, discusses the role of chemoimmunotherapy in chronic lymphocytic leukemia.

Dr. Hill on Next Steps for Research Exploring CAR T-Cell Therapy in MCL

October 26th 2020

Brian T. Hill, MD, PhD, discusses next steps for research examining CAR T-cell therapy in mantle cell lymphoma.

Dr. Atkins on the Impact of Georgetown Lombardi Cancer Center Consortium on Sarcoma Treatment

October 26th 2020

Michael B. Atkins, MD, discusses the impact of the Georgetown Lombardi Cancer Center Consortium on the treatment of patients with sarcoma.

Dr. Atkins on the Importance of the Georgetown Lombardi Cancer Center Consortium

October 26th 2020

Michael B. Atkins, MD, discusses the importance of the Georgetown Lombardi Cancer Center Consortium.

Dr. Gronchi on the Results of the TRASTS Trial in Soft Tissue Sarcoma

October 23rd 2020

Alessandro Gronchi, MD, discusses the results of the phase 2 TRASTS trial in soft tissue sarcoma.

Dr. Ahn on the Evolution of Targetable Alterations in CRC

October 23rd 2020

Daniel H. Ahn, DO, discusses the evolution of targetable alterations in colorectal cancer.

Dr. Mahal on the Potential Role of Race in Prostate Cancer Disparities

October 23rd 2020

Brandon Mahal, MD, discusses the potential role of race with regard to molecular disparities among men with prostate cancer.

Dr. Baskin on Treatment Considerations in Prostate Cancer

October 23rd 2020

Monica L. Baskin, PhD, discusses treatment considerations in prostate cancer.

Dr. Skarbnik on Selecting Between BTK Inhibitors in MCL

October 23rd 2020

Alan P. Z. Skarbnik, MD, discusses factors to consider in selecting between BTK inhibitors in mantle cell lymphoma.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Awan on Treatment Options in the First Relapsed Setting of CLL

October 23rd 2020

Farrukh Awan, MD, discusses treatment options in the first relapsed setting in patients with chronic lymphocytic leukemia.

Dr. Azad on the Significance of the PROfound Trial in mCRPC

October 23rd 2020

Arun Azad, PhD, discusses the significance of the PROfound trial in metastatic castration-resistant prostate cancer.

Dr. Kantoff on Future Research Efforts in Prostate Cancer

October 23rd 2020

Philip W. Kantoff, MD, discusses future research efforts in prostate cancer.

Dr. Shore on Unmet Needs in Nonmetastatic CRPC

October 23rd 2020

Neal D. Shore, MD, FACS, discusses unmet needs in nonmetastatic castration-resistant prostate cancer.